LIRA-ADD2SGLT2i – New Evidence on Combing GLP-1 RA and SGLT2i Therapies (https://doi.org/10.1111/dom.13978)

Abstract

This multinational randomised controlled trial provides new evidence of the benefits of adding liraglutide 1.8 mg od (vs placebo) in patients with type 2 diabetes who have suboptimal glycemic control despite stable dosing with an SGLT2 inhibitor + Metformin. After 6 months treatment, average reductions in HbA1c were 0.98% after liraglutide versus 0.3% following placebo (P<0.001). Corresponding weight reductions were −2.81 kg vs 1.99 kg (P=0.077). Fifty-one percent of liraglutide-treated patients achieved an HbA1c <7%, and the combination was generally well tolerated. This trial will add to the growing evidence that SGLT2 inhibitors and GLP-1 RAs such as liraglutide can be usefully combined.